Sodium Aluminum Phosphate vs Blue Dye 2: which is worse?

What is Sodium Aluminum Phosphate?

Sodium aluminum phosphate (SALP) is a leavening acid and food additive used in baked goods, particularly self-rising flour and baking powder. It provides a slow, sustained leavening action during baking. SALP is also used as an emulsifying salt in processed cheese products.

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

Documented risks

Sodium Aluminum Phosphate: The primary health concern with SALP is aluminum exposure. Dietary aluminum intake has been studied in relation to neurotoxicity, and there is ongoing scientific debate about whether chronic dietary aluminum exposure contributes to Alzheimer's disease risk. EFSA's 2008 review of dietary aluminum exposure concluded that the tolerable weekly intake (TWI) was being exceeded by some European populations based on total dietary aluminum sources, raising concern. A 2011 EFSA risk assessment noted that certain high-aluminum sources (including baked goods from SALP-containing leavening agents) contributed meaningfully to total dietary aluminum. The WHO has set a PTWI (provisional tolerable weekly intake) of 2 mg/kg body weight/week for total aluminum. However, the causal link between dietary aluminum from food-grade SALP and Alzheimer's disease has not been definitively established in human studies.

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.